High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday.
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
AbbVie still looks like a compelling buy at its all-time high.
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]
Abbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now. On May 27, analyst David Roman from Goldman Sachs maintained a “Buy” rating on the company’s stock and reduced the price objective to $113.00 from $121.00. The analyst’s rating is supported by several factors that highlight improvements in fundamentals and an attractive […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.